Olink Bioscience and Olink Genomics in a project aimed to improve cancer treatment
Olink Bioscience and its sister company Olink Genomics is participating in the project "Companion Diagnostics Initiative" which is financed by Vinnova and aims to develop improved cancer diagnostics to increase survival rate of patients with colorectal cancer. The project is coordinated by Professor Mats Nilsson at the Department of genetics and pathology and involves several clinical and pre-clinical research groups at Uppsala University.
Olink Bioscience provides its proprietary in situ PLA(TM), a proximity ligation assay technology that extends the capability of traditional immunofluorescence and immunohistochemistry to include direct detection of proteins, protein interaction, and modifications with unparalleled specificity and sensitivity. Target proteins are detected with single molecule resolution, allowing digital quantification and information about the exact localization of the target. Furthermore, the proteins can be studied at normal expression levels in fixed cells and tissue sections.
Olink Genomics participate with its Selector Technology(TM) which provides intelligent high-performance solutions to remove bottlenecks associated with targeted resequencing using next generation sequencing instruments. Selector Technology offers high sequencing coverage, convenience and scalability, providing scientists with superior tools for large-scale genomic analyses without the use of expensive, dedicated instrumentation.
"Cancer drugs of today are very expensive, and each drug only targets a sub-population of all patients with colorectal cancer. Duolink® will therefore be a great tool to identify new biomarkers that can be used for identification of patients that will benefit from cancer treatment" says Dr. Mats Gullberg, CTO of Olink Bioscience.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
